New cream could help kids with 'Butterfly Skin' heal faster

NCT ID NCT07482787

Recruiting now Disease control Sponsor: Paradigm Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Aug 14, 2026 · Updated 5 times

Summary

This phase 3 trial tests whether a cream called SD-101 can help close wounds in children with epidermolysis bullosa (EB), a condition that causes fragile, blistering skin. About 80 children aged 1 month to 12 years will apply the cream or a placebo to their whole body for 2 months. The main goal is to see if the cream helps a target wound close completely within one month.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SD-101 (allantoin) cream
What this could lead to: If it works, this could provide a safe, at-home cream to help close wounds faster in children with epidermolysis bullosa.
What could go wrong: This is still a placebo-controlled trial, so it's not yet proven to work. The cream may not be more effective than placebo, and results may not apply to all types of EB.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EPIDERMOLYSIS BULLOSA (EB) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

epidermolysis bullosa epidermolysis bullosa simplex junctional epidermolysis bullosa, non-Herlitz type Pruritus recessive dystrophic epidermolysis bullosa

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EPIDERMOLYSIS BULLOSA (EB)

Contacts and locations

Locations

Mission Dermatology
RECRUITING

Rancho Santa Margarita, California, 92688, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.